Clinical Applications of Fetal Cell-Free DNA: State of the Science.
cell‐free DNA (cfDNA)
noninvasive prenatal screening (NIPS)
noninvasive prenatal testing (NIPT)
prenatal genetic testing
Journal
Journal of midwifery & women's health
ISSN: 1542-2011
Titre abrégé: J Midwifery Womens Health
Pays: United States
ID NLM: 100909407
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
revised:
16
06
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
aheadofprint
Résumé
Advances in technology have correlated with expanding prenatal genetic testing options for pregnant people. Leading medical organizations recommend cell-free DNA as the most sensitive screening test for trisomies 13, 18, and 21, as well as for fetal sex chromosome aneuploidies. The commercially available testing options go beyond these recommended tests, and prenatal care professionals should be familiar with the tests that their patients may choose despite being beyond the scope of current medical recommendations. This article explains updates in cell-free DNA technology and clinical considerations for prenatal care professionals, recognizing that this is a rapidly changing field of science and health care.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 by the American College of Nurse‐Midwives.
Références
American College of Obstetricians and Gynecologists. Screening for fetal chromosomal abnormalities: ACOG practice bulletin, number 226. Obstet Gynecol. 2020;136(4):e48‐e69. doi:10.1097/AOG.0000000000004084
Prenatal genetic screening tests. American College of Obstetricians and Gynecologists website. Updated October 2020. Accessed January 10, 2024. https://www.acog.org/womens‐health/faqs/prenatal‐genetic‐screening‐tests
Grace MR, Hardisty E, Dotters‐Katz SK, Vora NL, Kuller JA. Cell‐free DNA screening: complexities and challenges of clinical implementation. Obstet Gynecol Surv. 2016;71(8):477‐487. doi:10.1097/OGX.0000000000000342
Ravitsky V, Roy MC, Haidar H, et al. The emergence and global spread of noninvasive prenatal testing. Annu Rev Genomics Hum Genet. 2021;22:309‐338. doi:10.1146/annurev‐genom‐083118‐015053
Rosner M, Kolbe T, Hengstschläger M. Fetomaternal microchimerism and genetic diagnosis: on the origins of fetal cells and cell‐free fetal DNA in the pregnant woman. Mutat Res Rev Mutat Res. 2021;788:108399. doi:10.1016/j.mrrev.2021.108399
Tsao DS, Silas S, Landry BP, et al. A novel high‐throughput molecular counting method with single base‐pair resolution enables accurate single‐gene NIPT. Sci Rep. 2019;9(1):14382. doi:10.1038/s41598‐019‐50378‐8
Hui L, Ellis K, Mayen D, et al. Position statement from the International Society for Prenatal Diagnosis on the use of non‐invasive prenatal testing for the detection of fetal chromosomal conditions in singleton pregnancies. Prenat Diagn. 2023;43(7):814‐828. doi:10.1002/pd.6357
LeFevre NM, Sundermeyer RL. Fetal aneuploidy: screening and diagnostic testing. Am Fam Physician. 2020;101(8):481‐488.
American College of Obstetricians and Gynecologists. Practice bulletin no. 162: prenatal diagnostic testing for genetic disorders. Obstet Gynecol. 2016;127(5):e108‐e122. doi:10.1097/AOG.0000000000001405
Acreman ML, Bussolaro S, Raymond YC, Fantasia I, Rolnik DL, Da Silva Costa F. The predictive value of prenatal cell‐free DNA testing for rare autosomal trisomies: a systematic review and meta‐analysis. Am J Obstet Gynecol. 2023;228(3):292‐305.e6. doi:10.1016/j.ajog.2022.08.034
Badeau M, Lindsay C, Blais J, et al. Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. Cochrane Database Syst Rev. 2017;11(11):CD011767. doi:10.1002/14651858.CD011767.pub2
Non‐invasive prenatal testing: an advocacy toolkit for obstetric health care professionals and patients. American College of Obstetricians and Gynecologists website. Accessed December 7, 2023. https://www.acog.org/advocacy/policy‐priorities/non‐invasive‐prenatal‐testing
Latendresse G, Deneris A. An update on current prenatal testing options: first trimester and noninvasive prenatal testing. J Midwifery Womens Health. 2015;60(1):24‐36. doi:10.1111/jmwh.12228
Dungan JS, Klugman S, Darilek S, et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general‐risk population: an evidence‐based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(2):100336. doi:10.1016/j.gim.2022.11.004
Nagaoka SI, Hassold TJ, Hunt PA. Human aneuploidy: mechanisms and new insights into an age‐old problem. Nat Rev Genet. 2012;13(7):493‐504. doi:10.1038/nrg3245
Rare disease database. National Organization of Rare Disorders website. Accessed January 18, 2024. https://rarediseases.org/rare‐diseases/
Down syndrome. Centers for Disease Control and Prevention website. Updated October 10, 2023. Accessed January 22, 2024. https://www.cdc.gov/ncbddd/birthdefects/downsyndrome.html#ref
Genetic and Rare Disease Information Center. Browse by disease. National Institutes of Health website. Updated January, 2024. Accessed December 9, 2023. https://rarediseases.info.nih.gov/diseases?category=&page=1&letter=&search=
Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell‐free DNA in maternal blood in screening for aneuploidies: updated meta‐analysis. Ultrasound Obstet Gynecol. 2017;50(3):302‐314. doi:10.1002/uog.17484
Monaghan TF, Rahman SN, Agudelo CW, et al. Foundational statistical principles in medical research: sensitivity, specificity, positive predictive value, and negative predictive value. Medicina (Kaunas). 2021;57(5):503. doi:10.3390/medicina57050503
Society for Maternal‐Fetal Medicine (SMFM), Prabhu M, Kuller JA, Biggio JR. Society for Maternal‐Fetal Medicine consult series #57: evaluation and management of isolated soft ultrasound markers for aneuploidy in the second trimester. Am J Obstet Gynecol. 2021;225(4):B2‐B15. doi:10.1016/j.ajog.2021.06.079
Zhang J, Li J, Saucier JB, et al. Non‐invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell‐free fetal DNA. Nat Med. 2019;25(3):439‐447. doi:10.1038/s41591‐018‐0334‐x
Dar P, Jacobsson B, MacPherson C, et al. Cell‐free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation. Am J Obstet Gynecol. 2022;227(2):259.e1.e1‐259.e14. doi:10.1016/j.ajog.2022.01.019
Scott F, Bonifacio M, Sandow R, Ellis K, Smet ME, McLennan A. Rare autosomal trisomies: important and not so rare. Prenat Diagn. 2018;38(10):765‐771. doi:10.1002/pd.5325
Benn P, Malvestiti F, Grimi B, Maggi F, Simoni G, Grati FR. Rare autosomal trisomies: comparison of detection through cell‐free DNA analysis and direct chromosome preparation of chorionic villus samples. Ultrasound Obstet Gynecol. 2019;54(4):458‐467. doi:10.1002/uog.20383
Panorama: noninvasive prenatal testing. Natera website. Accessed December 18, 2023. https://www.natera.com/womens‐health/panorama‐nipt‐prenatal‐screening/
Add NIPT to your portfolio. Illumina website. Accessed January 21, 2024. https://www.illumina.com/clinical/reproductive‐genetic‐health/nipt/sendout‐testing‐for‐labs.html
MaterniT 21 PLUS. Labcorp website. Accessed January 21, 2024. https://womenshealth.labcorp.com/providers/prenatal‐screening/noninvasive‐prenatal‐testing/maternit‐21‐plus
QNatal Advanced. Quest Diagnostics website. Accessed January 28, 2024. https://www.questdiagnostics.com/healthcare‐professionals/clinical‐education‐center/faq/faq167
UNITY Complete for providers. Billion to One website. Accessed January 21, 2024. https://unityscreen.com/providers/
Mohan P, Lemoine J, Trotter C, et al. Clinical experience with non‐invasive prenatal screening for single‐gene disorders. Ultrasound Obstet Gynecol. 2022;59(1):33‐39. doi:10.1002/uog.23756
Miceikaitė I, Hao Q, Brasch‐Andersen C, et al. Comprehensive noninvasive fetal screening by deep trio‐exome sequencing. N Engl J Med. 2023;389(21):2017‐2019. doi:10.1056/NEJMc2307918
American College of Obstetricians and Gynecologists. Practice bulletin no. 181: prevention of Rh D alloimmunization. Obstet Gynecol. 2017;130(2):e57‐e70. doi:10.1097/AOG.0000000000002232
Alford B, Landry BP, Hou S, et al. Validation of a non‐invasive prenatal test for fetal RhD, C, c, E, K and Fya antigens. Sci Rep. 2023;13(1):12786. doi:10.1038/s41598‐023‐39283‐3
Yang H, Llewellyn A, Walker R, et al. High‐throughput, non‐invasive prenatal testing for fetal rhesus D status in RhD‐negative women: a systematic review and meta‐analysis. BMC Med. 2019;17(1):37. doi:10.1186/s12916‐019‐1254‐4
Saramago P, Yang H, Llewellyn A, et al. High‐throughput non‐invasive prenatal testing for fetal rhesus D status in RhD‐negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. Health Technol Assess. 2018;22(13):1‐172. doi:10.3310/hta22130
Moise KJ Jr, Hashmi SS, Markham K, Argoti PS, Bebbington M. Cell free fetal DNA to triage antenatal rhesus immune globulin: is it really cost‐effective in the United States? Prenat Diagn. 2019;39(3):238‐247. doi:10.1002/pd.5415
Deng C, Liu J, Liu S, et al. Maternal and fetal factors influencing fetal fraction: a retrospective analysis of 153,306 pregnant women undergoing noninvasive prenatal screening. Front Pediatr. 2023;11:1066178. doi:10.3389/fped.2023.1066178
MacKinnon HJ, Kolarova TR, Katz R, et al. The impact of maternal autoimmune disease on cell‐free DNA test characteristics. Am J Obstet Gynecol MFM. 2021;3(6):100466. doi:10.1016/j.ajogmf.2021.100466
Palomaki GE, Kloza EM. Prenatal cell‐free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing. Genet Med. 2018;20(11):1312‐1323. doi:10.1038/gim.2018.22
Dugoff L, Koelper NC, Chasen ST, et al. Cell‐free DNA screening for trisomy 21 in twin pregnancy: a large multicenter cohort study. Am J Obstet Gynecol. 2023;229(4):435.e1.e1‐435.e1.e7. doi:10.1016/j.ajog.2023.04.002
La Verde M, De Falco L, Torella A, et al. Performance of cell‐free DNA sequencing‐based non‐invasive prenatal testing: experience on 36,456 singleton and multiple pregnancies. BMC Med Genomics. 2021;14(1):93. doi:10.1186/s12920‐021‐00941‐y
Benn P, Rebarber A. Non‐invasive prenatal testing in the management of twin pregnancies. Prenat Diagn. 2021;41(10):1233‐1240. doi:10.1002/pd.5989
Kantor V, Jelsema R, Xu W, et al. Non‐invasive prenatal screening for fetal triploidy using single nucleotide polymorphism‐based testing: differential diagnosis and clinical management in cases showing an extra haplotype. Prenat Diagn. 2022;42(8):994‐999. doi:10.1002/pd.6169
Heesterbeek CJ, Aukema SM, Galjaard RH, et al. Noninvasive prenatal test results indicative of maternal malignancies: a nationwide genetic and clinical follow‐up study. J Clin Oncol. 2022;40(22):2426‐2435. doi:10.1200/JCO.21.02260
Ayala NK, Kole MB, Forcier M, Halliday J, Russo ML. Sex discordance between cell‐free fetal DNA and mid‐trimester ultrasound: a modern conundrum. Prenat Diagn. 2020;40(4):514‐516. doi:10.1002/pd.5576
Kamoun C, Rossi W, Kilberg MJ. Ethical concerns surrounding sex prediction using noninvasive prenatal screening from pediatric endocrinologists' perspective. J Genet Couns. 2023;32(5):937‐941. doi:10.1002/jgc4.1649
Steffensen EH, Skakkebaek A, Gadsbøll K, et al. Inclusion of sex chromosomes in noninvasive prenatal testing in Asia, Australia, Europe and the USA: a survey study. Prenat Diagn. 2023;43(2):144‐155. doi:10.1002/pd.6322
Parobek CM, Russo ML, Lewkowitz AK. Privacy risks in prenatal aneuploidy and carrier screening: what obstetricians and their patients need to know. Obstet Gynecol. 2021;137(6):1074‐1079. doi:10.1097/AOG.0000000000004387
Parobek CM, Russo ML, Lewkowitz AK. Privacy practices using genetic data from cell‐free DNA aneuploidy screening. Genet Med. 2021;23(9):1746‐1752. doi:10.1038/s41436‐021‐01205‐x
Parobek CM, Thorsen MM, Has P, et al. Video education about genetic privacy and patient perspectives about sharing prenatal genetic data: a randomized trial. Am J Obstet Gynecol. 2022;227(1):87.e1.e1‐87.e13. doi:10.1016/j.ajog.2022.03.047
Xie X, Wang M, Goh ESY, et al. Noninvasive prenatal testing for trisomies 21, 18, and 13, sex chromosome aneuploidies, and microdeletions in average‐risk pregnancies: a cost‐effectiveness analysis. J Obstet Gynaecol Can. 2020;42(6):740‐749.e12. doi:10.1016/j.jogc.2019.12.007
Coverage scorecards. Coalition for Access to Prenatal Screening website. Updated February 28, 2023. Accessed December 18, 2023. https://capsprenatal.com/coverage‐scorecards/
Abortion bans in cases of sex or race selection or genetic anomaly. Guttmacher Institute website. Published August 31, 2023. Accessed November 27, 2023. https://www.guttmacher.org/state‐policy/explore/abortion‐bans‐cases‐sex‐or‐race‐selection‐or‐genetic‐anomaly
Genetic non‐invasive prenatal screening tests may have false results: FDA safety communication. US Food and Drug Administration website. Published April 19, 2022. Accessed December 31, 2023. https://www.fda.gov/medical‐devices/safety‐communications/genetic‐non‐invasive‐prenatal‐screening‐tests‐may‐have‐false‐results‐fda‐safety‐communication
American College of Nurse‐Midwives. Shared Decision‐Making in Midwifery Care. American College of Nurse‐Midwives; 2016. Accessed January 15, 2024. http://www.midwife.org/ACNM/files/ACNMLibraryData/UPLOADFILENAME/000000000305/Shared‐Decision‐Making‐in‐Midwifery‐Care‐Dec‐2016.pdf
Wright H, Zhao L, Birks M, Mills J. Genomic literacy of registered nurses and midwives in Australia: a cross‐sectional survey. J Nurs Scholarsh. 2019;51(1):40‐49. doi:10.1111/jnu.12440
Dettwyler SA, Zielinski RE, Yashar BM. Certified nurse‐midwives' experiences with provision of prenatal genetic screening: a case for interprofessional collaboration. J Perinat Neonatal Nurs. 2019;33(4):E3‐E14. doi:10.1097/JPN.0000000000000440
Dubois ML, Winters PD, Rodrigue MA, Gekas J. Patient attitudes and preferences about expanded noninvasive prenatal testing. Front Genet. 2023;14:976051. doi:10.3389/fgene.2023.976051
van Schendel RV, Page‐Christiaens GCML, Beulen L, et al. Women's experience with non‐invasive prenatal testing and emotional well‐being and satisfaction after test‐results. J Genet Couns. 2017;26(6):1348‐1356. doi:10.1007/s10897‐017‐0118‐3
Delgado A, Schulkin J, Macri CJ. Prenatal genetic screening and diagnostic testing: assessing patients' knowledge, clinical experiences, and utilized resources in comparison to provider's perceptions. AJP Rep. 2022;12(1):e27‐e32. doi:10.1055/s‐0041‐1742236
Gammon BL, Kraft SA, Michie M, Allyse M. “I think we've got too many tests!”: prenatal providers' reflections on ethical and clinical challenges in the practice integration of cell‐free DNA screening. Ethics Med Public Health. 2016;2(3):334‐342. doi:10.1016/j.jemep.2016.07.006
Carbone L, Cariati F, Sarno L, et al. Non‐invasive prenatal testing: current perspectives and future challenges. Genes (Basel). 2020;12(1):15. doi:10.3390/genes12010015
Jenkins LA, Deans ZC, Lewis C, Allen S. Delivering an accredited non‐invasive prenatal diagnosis service for monogenic disorders and recommendations for best practice. Prenat Diagn. 2018;38(1):44‐51. doi:10.1002/pd.5197
Rose NC, Barrie ES, Malinowski J, et al. Systematic evidence‐based review: the application of noninvasive prenatal screening using cell‐free DNA in general‐risk pregnancies. Genet Med. 2022;24(7):1379‐1391. doi:10.1016/j.gim.2022.03.019
Brand H, Whelan CW, Duyzend M, et al. High‐resolution and noninvasive fetal exome screening. N Engl J Med. 2023;389(21):2014‐2016. doi:10.1056/NEJMc2216144
Maktabi MA, Vossaert L, Van den Veyver IB. Cell‐based noninvasive prenatal testing (cbNIPT)‐a review on the current developments and future prospects. Clin Obstet Gynecol. 2023;66(3):636‐648. doi:10.1097/GRF.0000000000000798